ClinicalTrials.gg
CompletedNCT07940088ATO-IMCUpdated Nov 16, 2026

Pharmacist-Led Antimicrobial Therapy Optimization in Intermediate Care

An interventional study of Pharmacist-led antimicrobial therapy optimization in Infections, Bacterial Infections and Critical Illness, sponsored by Clinica las Condes, Chile. Completed at 1 site in Chile. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Primary conditionBacterial InfectionsRegistry: InfectionsReclassifiedWhy we changed it
Registry
Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Bacterial Infections
Why
  1. The study's listed conditions name Bacterial Infections, a narrower term within Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Clinica las Condes, Chile · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Feb 2024, registered Nov 2026).
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Bacterial Infections with a site in Chile — none open to participants now, none under way, none of them phase 3. Bacterial Infections · Chile.

Enrollment
8th of 10
180 · median 440
Started
2024
the only one that year
No phase
Only one
of the 11
Registered
11th of 11
by date
Lead sponsor
1 of 11
Clinica las Condes, Chile

Among the 11 studies in Bacterial Infections with a site in Chile, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2024, is the only one with no phase, and was the 11th registered.

Bacterial Infections

585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

None of the 11 studies in Bacterial Infections with a site in Chile is open now. The open studies under Bacterial Infections, anywhere →

Who these studies take

Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Bacterial Infections with a site in Chile as a file.
02

Study summary

Inappropriate antimicrobial prescribing is common in hospitalised patients and is associated with worse outcomes. Clinical pharmacists are core members of antimicrobial stewardship teams, but the evidence comes almost entirely from intensive care units and from undifferentiated hospital-wide analyses.

This trial tested whether adding pharmacist-led antimicrobial therapy optimization to standard care improves the quality of antibiotic prescribing in an intermediate care unit, a setting where antimicrobial therapy is often the main therapeutic intervention.

Adults admitted with an active infection and antibiotics started within the previous 72 hours were randomly assigned to standard care or to standard care plus a structured daily pharmacist review of five prescribing domains during the first four days. The primary outcome was optimal prescribing at day 4, defined as meeting all five domains simultaneously.

Read the detailed description

The intervention consisted of a structured daily review of indication, spectrum selection, dose and frequency, route of administration and duration of therapy.

Dose optimisation included therapeutic drug monitoring of vancomycin and amikacin, adjustment for renal function and renal replacement therapy, weight-based and albumin-guided correction, and extended or continuous infusion of beta-lactams where pharmacokinetic optimisation was indicated.

Recommendations were directed to the attending physician, who decided whether to implement them. The pharmacist did not modify prescriptions independently. Acceptance was defined as implementation documented in the electronic health record within 24 hours of communication.

After the day 4 assessment, participants in both arms could receive pharmaceutical intervention as clinically indicated.

03

Conditions studied

  • Infections
  • Bacterial Infections
  • Critical Illness

Browse trials for

Keywords

  • antimicrobial stewardship
  • clinical pharmacist
  • intermediate care
  • antibiotic prescribing quality
  • days of therapy
  • pharmaceutical intervention
04

In context

Bacterial Infections Reclassified

585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

This study's enrollment of 180 is above the median of 84 across 383 interventional studies indexed under Bacterial Infections.

Browse Bacterial Infections studies →

Lead sponsor

Clinica las Condes, Chile is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Compared within Bacterial Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Admitted to the Intermediate Care Unit
  • Active infection requiring systemic antibiotic therapy, defined as clinical signs and symptoms of infection with initiation of systemic antibiotic therapy by the treating physician
  • Systemic antibiotic therapy initiated less than 72 hours before enrolment

Exclusion criteria

Exclusion Criteria:

  • SOFA score greater than 6 at enrolment
  • Admission to, or transfer from, an intensive care unit at enrolment
  • Expected hospital stay shorter than 48 hours
  • Terminal illness with expected survival shorter than 30 days
  • Pregnancy
  • Inability to provide with no legal representative available
  • Previous enrolment in the study during the same hospitalisation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Pharmacist-led ATO

    Standard care plus pharmacist-led antimicrobial therapy optimization, with structured daily review of five prescribing domains during the first four days from randomisation.

    Other: Pharmacist-led antimicrobial therapy optimization

  • No intervention
    Standard care

    Standard medical care according to institutional protocols, with no pharmaceutical intervention during the first four days from randomisation. From day 4 onwards, participants in this arm could also receive pharmacist-led optimization.

Interventions

  • OtherPharmacist-led antimicrobial therapy optimization

    Structured daily review of indication, spectrum selection, dose and frequency, route of administration and duration of antimicrobial therapy, delivered as recommendations to the attending physician.

    Also known as: ATO

07

What researchers measure

Primary outcomes

  1. Optimal antibiotic prescribing

    Proportion of participants whose antibiotic prescription simultaneously met all five standardised criteria: appropriate indication, correct spectrum coverage, adequate dose and frequency, suitable route of administration and appropriate duration. A prescription failing any single domain was classified as optimizable.

    Time frame: Day 4 after randomisation

Secondary outcomes

  1. Favourable clinical response

    Composite requiring all of: reduction of 50 percent or more in procalcitonin or an absolute value below 0.5 ng/mL, or reduction of 50 percent or more from peak C-reactive protein; decrease in symptoms of infection in the treating physician's opinion; decrease in the temperature curve from the thermal maximum; absence of hypothermia (temperature 35 degrees Celsius or above); white blood cell count below 11 x 10\^9/L; and no change in antimicrobial therapy involving escalation.

    Time frame: Day 7 after randomisation

  2. Acceptance of pharmacist recommendations

    Number of recommendations implemented and documented in the electronic health record within 24 hours of communication, divided by the total number of recommendations made.

    Time frame: Days 1 to 4 after randomisation

  3. Days of therapy

    Sum of days on which each individual antibiotic was received, regardless of dose, reported per participant and standardised per 1,000 patient-bed-days.

    Time frame: From randomisation to the end of antibiotic treatment, up to 60 days

  4. Antibiotic-related adverse reactions

    Adverse reactions recorded in either arm as a reason for modifying antimicrobial therapy. Ascertainment was limited to reactions severe enough to prompt a change in treatment.

    Time frame: From randomisation to the end of antibiotic treatment, up to 60 days

  5. Clinical cure

    Complete resolution of the signs and symptoms of infection.

    Time frame: End of antibiotic treatment or hospital discharge, whichever occurred first, up to 60 days

  6. All-cause mortality

    Death from any cause, assessed in hospital and at 28 and 90 days.

    Time frame: From randomisation to hospital discharge, up to 60 days; Day 28 after randomisation; Day 90 after randomisation

  7. Clinical deterioration requiring escalation of care

    Deterioration of the clinical condition requiring an increase in the level of care.

    Time frame: From randomisation to hospital discharge, up to 60 days

  8. Transfer to intensive care

    Transfer from the intermediate care unit to an intensive care unit.

    Time frame: From randomisation to hospital discharge, up to 60 days

  9. Hospital length of stay

    Total days of hospitalisation from admission to discharge.

    Time frame: From admission to discharge, up to 60 days

08

Study locations

1 site
  • Clinica Las Condes, Intermediate Care Unit
    Santiago, Santiago Metropolitan 7591046, Chile
09

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Feb 2025, 11 months.

Of 57 non-industry interventional studies with no phase under Bacterial Infections, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's 11 months is below that.

Counting every sponsor, half of 61 studies reached it within 24 months; a quarter within 11 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartActual
Feb 24, 2024
Primary completionActual
Feb 1, 2025
CompletionActual
May 2, 2025
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07940088
Lead sponsor
Clinica las Condes, Chile
Collaborators
Finis Terrae University, University of Chile
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Feb 24, 2024
Primary completion
Feb 1, 2025
Completion
May 2, 2025
Last update
Nov 16, 2026

Study contacts

Natalia Caceres Astudillo, PharmD
principal investigator · Clinica Las Condes
Andres Giglio, MD, MSc, MHA, MPH
study director · Clinica Las Condes

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion